Abstract: A method of determining patient responsiveness to a drug by the use of spectroscopy to obtain patient metabolite data and relating that data to data obtained from a statistically significant group of patients taking the same drug in order to obtain a result indicating responsiveness of a particular patient to treatment with a particular drug.

Abstract: A method of predicting the responsiveness of a patient to a pharmaceutical drug by measuring metabolites in a biological sample from the patient is disclosed. Specific drug metabolites in blood from breast cancer patients are analyzed using NMR spectroscopy whereby responsiveness of the human cancer patients before, during and after treatment with a cancer drug is assessed by measuring the change in clinical outcomes. Data obtained is used to identify particular NMR resonances that are strongly correlated with whether the patient is responsive or resistant to each drug. As such, models for predicting the responsiveness of a patient to each drug based on metabolites from the patient are provided.

Abstract: The invention relates generally to monitoring the immune system response, and more specifically to identifying and diagnosing patients who are at risk for developing a disease or disorder associated with altered immune system response or who have been treated with a drug such as an immunosuppressant and using metabolomics and making a comparison against a database of patients to determine if an effective immune response has been elicited.

Abstract: A method of predicting the responsiveness of a patient to a pharmaceutical drug by measuring metabolites in a biological sample from the patient is disclosed. Specific drug metabolites in blood from breast cancer patients are analyzed using NMR spectroscopy whereby responsiveness of the human cancer patients before, during and after treatment with a cancer drug is assessed by measuring the change in clinical outcomes. Data obtained is used to identify particular NMR resonances that are strongly correlated with whether the patient is responsive or resistant to each drug. As such, models for predicting the responsiveness of a patient to each drug based on metabolites from the patient are provided.

Abstract: A method of predicting the responsiveness of a patient to a pharmaceutical drug by measuring metabolites in a biological sample from the patient is disclosed. Specific drug metabolites in blood from breast cancer patients are analyzed using NMR spectroscopy whereby responsiveness of the human cancer patients before, during and after treatment with a cancer drug is assessed by measuring the change in clinical outcomes. Data obtained is used to identify particular NMR resonances that are strongly correlated with whether the patient is responsive or resistant to each drug. As such, models for predicting the responsiveness of a patient to each drug based on metabolites from the patient are provided.

Abstract: A method of determining patient responsiveness to a drug by the use of spectroscopy to obtain patient metabolite data and relating that data to data obtained from a statistically significant group of patients taking the same drug in order to obtain a result indicating responsiveness of a particular patient to treatment with a particular drug.